amarantus bioscience holdings inc ambs amarantus bioscience holdings inc email alerts amarantus bioscience holdings inc on facebook amarantus bioscience holdings inc on linkedin amarantus bioscience holdings inc on twitter amarantus bioscience holdings inc on googleplus amarantus bioscience holdings inc rss pioneering research developing therapeutic and diagnostic products for neurological disorders and orphan indications learn more pioneering research developing therapeutic and diagnostic products for neurological disorders and orphan indications learn more pioneering research developing therapeutic and diagnostic products for neurological disorders and orphan indications learn more therapeutics pipeline amarantus specializes in the identification and acquisition of undervalued assets that have the potential to address huge unmet medical needs we are dedicated to building and developing a robust pipeline of therapeutic candidates in neurology and ophthalmology diseases and regenerative medicine view pipeline phase preclinical phase  phase  phase  market eltoprazine parkinsons pdlid preclinical phase completed phase  phase completed phase  phase in progress phase  phase not started market phase not started eltoprazine adult adhd preclinical phase completed phase  phase completed phase  phase in progress phase  phase not started market phase not started eltoprazine alzheimers aggression preclinical phase completed phase  phase in progress phase  phase not started phase  phase not started market phase not started ess intractable severe burns preclinical phase completed phase  phase completed phase  phase in progress phase  phase not started market phase not started manf retinitis pigmentosa preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started market phase not started manf parkinsons disease preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started market phase not started source develop and monetize highly undervalued biopharma assets three pillars of expected transformational growth amarantus has a focus on developing certain small molecules biologics and biomarkers surrounding intellectual property and proprietary technologies it owns therapeutics eltoprazine manf engineered skin substitute ess discovery phenoguard latest news april   •  am edt amarantus forms subsidiaries elto pharma to focus on cns disorders and manf therapeutics to focus on ophthalmology april   •  pm edt amarantus provides update on restructuring efforts and letter of intent with sed biomedical inc february   •  pm est amarantus enters into a letter of intent to acquire certain biotechnology assets from sed biomedical inc social media ambs results indicate that autologous esss reduce mortality  requirements for donor skin harvesting httpstcomdrkdfi august    pm investor presentation view our latest corporate presentation view presentation stock info view investor relations › otcpink ambs change volume market cap sign up for email alerts be the first to receive breaking news sign up today overview  amarantus bioscience holdings inc ambs amarantus bioscience holdings inc email alerts amarantus bioscience holdings inc on facebook amarantus bioscience holdings inc on linkedin amarantus bioscience holdings inc on twitter amarantus bioscience holdings inc on googleplus amarantus bioscience holdings inc rss home therapeutics pipeline overview navigation pipeline therapeutic pipeline phase preclinical phase  phase  phase  market eltoprazine parkinsons pdlid preclinical phase completed phase  phase completed phase  phase in progress phase  phase not started market phase not started eltoprazine adult adhd preclinical phase completed phase  phase completed phase  phase in progress phase  phase not started market phase not started eltoprazine alzheimers aggression preclinical phase completed phase  phase in progress phase  phase not started phase  phase not started market phase not started ess intractable severe burns preclinical phase completed phase  phase completed phase  phase in progress phase  phase not started market phase not started manf retinitis pigmentosa preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started market phase not started manf parkinsons disease preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started market phase not started sign up for email alerts be the first to receive breaking news sign up today contact  amarantus bioscience holdings inc ambs amarantus bioscience holdings inc email alerts amarantus bioscience holdings inc on facebook amarantus bioscience holdings inc on linkedin amarantus bioscience holdings inc on twitter amarantus bioscience holdings inc on googleplus amarantus bioscience holdings inc rss home contact amarantus bioscience holdings inc indiana stsan francisco ca united states lab perry parkwaysuite gaithersburg md  phone being updatedfax   first name last name email comments submit latest news april   •  am edt amarantus forms subsidiaries elto pharma to focus on cns disorders and manf therapeutics to focus on ophthalmology about amarantus bioscience holdings inc is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology psychiatry ophthalmology and regenerative medicine and diagnostics in neurology learn more sign up for email alerts be the first to receive breaking news sign up today investors  amarantus bioscience holdings inc ambs amarantus bioscience holdings inc email alerts amarantus bioscience holdings inc on facebook amarantus bioscience holdings inc on linkedin amarantus bioscience holdings inc on twitter amarantus bioscience holdings inc on googleplus amarantus bioscience holdings inc rss investor presentation download our latest investor presentation download home investors investors navigation email alerts tear sheet contacts rss news feed investor relations latest news amarantus forms subsidiaries elto pharma to focus on cns disorders and manf therapeutics to focus on ophthalmology apr   read press release latest financial results q  quarterly results mar   pdf html q filing html financials zip xls html xbrl stock information symbol otcpink ambs price change mkt cap volume company overview amarantus bioscience holdings inc is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology psychiatry ophthalmology and regenerative medicine and diagnostics in neurology the company’s lead therapeutic program eltoprazine is a small molecule indicated for the treatment of levodopainduced dyskinesia one of the most difficult problems facing patients with parkinson’s disease eltoprazine commenced a phase b clinical trial in the second quarter of  with results from the study expected in  eltoprazine is also being evaluated for the treatment of adult attention deficit hyperactivity disorder adhd and alzheimer’s aggression amarantus recently completed the acquisition of cutanogen corporation cutanogen from lonza walkersville inc a subsidiary of lonza group ltd cutanogen has an exclusive worldwide license to intellectual property rights associated with engineered skin substitute ess ess is a full thickness skin replacement product prepared from autologous patients own tissueengineered skin cells in development for the treatment of severe burns ess received orphan drug designation from the fda for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting amarantus expects to commence a phase  study of ess in the us in the third quarter of  amarantus is also developing manf mesencephalicastrocytederived neurotrophic factor which was discovered by the company’s own discovery platform phenoguard manf is being developed for the treatment of brain and ophthalmic disorders and has received orphan drug designation from the fda and the european medicines agency ema and the european medicines agency ema for the treatment of retinitis pigmentosa the company’s diagnostics division amarantus diagnostics is dedicated to the development and commercialization of neurology diagnostic products the company’s lead diagnostic product lympro test® is a blood based assay to diagnose alzheimer’s disease and is approved for investigational use only to be used in biotech and pharmaceutical clinical trials amarantus diagnostics is also developing msprecise® a proprietary nextgeneration dna sequencing ngs assay for the identification of patients with relapsingremitting multiple sclerosis rrms at first clinical presentation officers  directors executive leadership board of directors gerald e commissiong president  chief executive officer mr commissiong is president  ceo cofounder and a member of the board of directors of amarantus bioscience holdings inc mr… view full bio john w commissiong phd chief scientific officer dr commissiong has served as the chief scientific officer and a director of amarantus since cofounding the company in  prior to… view full bio rongguo ronald wei chief financial officer mr wei is a finance professional with more than  years of experience working in public and private corporations in the united states as… view full bio elise brownell phd senior vice president of operations and project management dr brownell joined amarantus in december  and has more than  years of biotechnology and pharmaceutical project management experience… view full bio curtis scribner md mba senior vice president of regulatory affairs dr scribner is an independent regulatory consultant in the bay area dr scribner was recently senior vice president of medical and… view full bio marc e faerber corporate controller and vice president of financial operations mr faerber joined amarantus in may  and has over thirty years of experience with over nineteen of those in life sciences his… view full bio joseph rubinfeld phd independent director dr rubinfeld is a renowned expert in the field of drug development and a cofounder of amgen one of the most successful companies in the… view full bio robert l harris independent director compliance officer mr harris has served as a member of the board of directors of amarantus since december  harris is a retired vice president of… view full bio donald d huffman independent director mr huffman currently serves as a director of dance biopharm inc a diabetes company entering phase  clinical development with an inhaled… view full bio steven spence director view full bio conn flanigan director view full bio john w commissiong phd chief scientific officer dr commissiong has served as the chief scientific officer and a director of amarantus since cofounding the company in  prior to… view full bio sign up for email alerts be the first to receive breaking news sign up today management team  amarantus bioscience holdings inc ambs amarantus bioscience holdings inc email alerts amarantus bioscience holdings inc on facebook amarantus bioscience holdings inc on linkedin amarantus bioscience holdings inc on twitter amarantus bioscience holdings inc on googleplus amarantus bioscience holdings inc rss home about navigation management team gerald e commissiong president  chief executive officer mr commissiong is president  ceo cofounder and a member of the board of directors of amarantus bioscience holdings inc mr commissiong has been responsible for leading the companys strategic transactions licensing research collaborations mergers and acquisitions and fund raising he has raised over of  million to acquire and develop assets to build a robust therapeutics and diagnostics pipeline prior to becoming ceo in october  mr commissiong was the chief operating officer prior to cofounding amarantus mr commissiong played professional football for the calgary stampeders of the canadian football league mr commissiong received a bsc in management science and engineering with a focus on financial decisions from stanford university john w commissiong phd chief scientific officer dr commissiong has served as the chief scientific officer and a director of amarantus since cofounding the company in  prior to amarantus dr commissiong served as the cso of neurotrophics inc and prescient neuropharma inc throughout his distinguished career dr commissiong has been focused on the discovery of novel neurotrophic factors for the treatment of neurodegenerative diseases as well as understanding the fundamental underlying biology of protoplasmic type astrocytes that secrete neurotrophic factors he was chief of the neural transplantation unit nindsnih from  where his research focused on identifying therapeutic approaches to spinal cord injury dr commissiong was head of the neurotrophic factors group nindsnih from  where he focused on developing technologies to systematically identify novel neurotrophic factors with applications for specific central nervous system disorders he cofounded prescient neuropharma in  and discovered manf in  the work pioneered by dr commissiong has led to significant advancements in the field of astrocyteneuron biology dr commissiong did his postdoctoral work in the lab preclin pharmac nimhnih concentrating on the application of quadrupole mass spectrometry in the analysis of neurotransmitters he holds a phd in neurophysiology from the university of southampton a msc in biochemical pharmacology from the university of southampton and a bs in biology and chemistry from the university of the west indies rongguo ronald wei chief financial officer mr wei is a finance professional with more than  years of experience working in public and private corporations in the united states as the chief financial officer of sed development management llc mr wei is responsible for oversight of all finance accounting reporting and taxation activities for that company prior to joining sed development management llc in  mr wei worked for several different us multinational and private companies including serving as controller at american silk mill llc from  serving as a senior financial analyst at air products  chemicals inc from  and serving as a financialaccounting analyst at first quality enterprise inc from  before mr wei came to the united states he worked as an equity analyst in hong yuan securities in beijing china concentrating on industrial and public company research and analysis mr wei is a certified public accountant and received his mba from the university of maryland and a master of business taxation from the university of minnesota mr wei also holds a master in business degree from tsinghua university and a bachelor degree from beihang university mr wei also serves as the chief financial officer of homeownusa elise brownell phd senior vice president of operations and project management dr brownell joined amarantus in december  and has more than  years of biotechnology and pharmaceutical project management experience with a proven track record of advancing programs through clinical development she serves as a life sciences entrepreneurial advisor for astia the nations premier entrepreneurial organization focused on womenled businesses dr brownell is also a member of the editorial advisory board for contract pharma magazine and previous chair of the leaders network program of women in consulting she is the cofounder of zephyrbiotech llc a project management firm dedicated to advancing therapeutic candidates through development to key inflection points for clients earlier dr brownell was a founding member head of project management and senior director of aerovance inc a venturebacked biotechnology company spun out from bayer healthcare where she created and managed effective team processes to bring product candidates into full scale clinical phase  and  development prior to aerovance dr brownell acted as head of project management for bayers biotechnology unit where she integrated project strategies to meet therapeutic and market needs other roles included building and negotiating partnerships with third parties to support development programs leading research teams through early benchtoclinic development phases as well as entrepreneurial investment experience with angel’s forum dr brownell received her ms mphil and phd in biology from yale university and her bs in biology from allegheny college curtis scribner md mba senior vice president of regulatory affairs dr scribner is an independent regulatory consultant in the bay area dr scribner was recently senior vice president of medical and regulatory affairs at rrd international llc dr scribner is a board certified physician in internal medicine and has direct experience in developing and running small and large clinical programs he joined rrd from intarcia therapeutics where he was the vice president of regulatory and quality affairs and chief regulatory officer previously dr scribner was chief regulatory consultant for quintiles consulting where he developed and wrote numerous nda bla ind ide k pma and maa applications prior to quintiles consulting dr scribner spent  years at fda where he held a variety of positions and was involved in reviewing products regulated by the center for biologics dr scribner holds an md from the university of colorado college of medicine an mba from the university of maryland college of business and management and a ba in biology from grinnell college marc e faerber corporate controller and vice president of financial operations mr faerber joined amarantus in may  and has over thirty years of experience with over nineteen of those in life sciences his experience has spanned fortune  companies to startups and everything in between during the past ten years mr faerber has been providing financial business and advisory services to a broad base of startup companies primarily in the fields of cardiology gastroenterology orthopedics diagnostics and biotechnology he has extensive experience managing transactions including the establishment of international organizations throughout europe and parts of asia international technology licensing and distribution mergers and acquisitions and numerous funding transactions including an initial public offering as well as other international business structural issues during mr faerbers career he has held various positions in finance and corporate management including cfo ceo and director mr faerber started his career at kpmg as a certified public accountant and he has a bachelor of sciences degree in business administration from providence college sign up for email alerts be the first to receive breaking news sign up today press releases  amarantus bioscience holdings inc ambs amarantus bioscience holdings inc email alerts amarantus bioscience holdings inc on facebook amarantus bioscience holdings inc on linkedin amarantus bioscience holdings inc on twitter amarantus bioscience holdings inc on googleplus amarantus bioscience holdings inc rss home news press releases navigation press releases all news        april   •  am edt amarantus forms subsidiaries elto pharma to focus on cns disorders and manf therapeutics to focus on ophthalmology april   •  pm edt amarantus provides update on restructuring efforts and letter of intent with sed biomedical inc february   •  pm est amarantus enters into a letter of intent to acquire certain biotechnology assets from sed biomedical inc february   •  am est amarantus announces passing of biotechnology legend dr joseph rubinfeld august   •  am edt amarantus announces publication of human clinical data for engineered skin substitute in the treatment of lifethreatening pediatric severe burns june   •  am edt amarantus announces cgmp manufacturing readiness for its engineered skin substitute ess program at lonza walkersville june   •  am edt amarantus completes sale of diagnostics division announces fiscal year  and first quarter  financial results may   •  am edt amarantus announces upcoming investor presentations april   •  am edt retired american burn association president dr david ahrenholz to present on engineered skin substitute ess at the vaticans third international conference on the progress of regenerative medicine and its cultural impact april   •  pm edt amarantus announces capital infusion            next » sign up for email alerts be the first to receive breaking news sign up today scientific advisory board  amarantus bioscience holdings inc ambs amarantus bioscience holdings inc email alerts amarantus bioscience holdings inc on facebook amarantus bioscience holdings inc on linkedin amarantus bioscience holdings inc on twitter amarantus bioscience holdings inc on googleplus amarantus bioscience holdings inc rss home about scientific advisory board navigation scientific advisory board lawrence m schwartz phd isenberg professor of integrative science at university of massachusettsscientist at pioneer valley life sciences instituteprofessor of biology at university of massachusetts amherstadjunct faculty in pathology baystate medical center dr lawrence m schwartz was appointed in  as the first isenberg professor of integrative science at the university of massachusetts dr schwartz is a professor in the biology department at the university of massachusetts as well as the founding director of the pioneer valley life sciences institute in springfield ma where he served as scientific director from  until  he also served as the director of the center of excellence in apoptosis his laboratory examines the molecular mechanisms that mediate cell death during normal development and in pathology one avenue of research focuses in acheron a novel gene cloned in the schwartz laboratory that regulates the differentiation and death of skeletal muscle and may play a role in the metastatic behaviors of some soft tissue tumors a second line of investigation examines the role of ubiquiton e ligases parkin and human homolog of ariadne in dopaminergic neuron survival john w commissiong phd chief scientific officer dr commissiong has served as the chief scientific officer and a director of amarantus since cofounding the company in  prior to amarantus dr commissiong served as the cso of neurotrophics inc and prescient neuropharma inc throughout his distinguished career dr commissiong has been focused on the discovery of novel neurotrophic factors for the treatment of neurodegenerative diseases as well as understanding the fundamental underlying biology of protoplasmic type astrocytes that secrete neurotrophic factors he was chief of the neural transplantation unit nindsnih from  where his research focused on identifying therapeutic approaches to spinal cord injury dr commissiong was head of the neurotrophic factors group nindsnih from  where he focused on developing technologies to systematically identify novel neurotrophic factors with applications for specific central nervous system disorders he cofounded prescient neuropharma in  and discovered manf in  the work pioneered by dr commissiong has led to significant advancements in the field of astrocyteneuron biology dr commissiong did his postdoctoral work in the lab preclin pharmac nimhnih concentrating on the application of quadrupole mass spectrometry in the analysis of neurotransmitters he holds a phd in neurophysiology from the university of southampton a msc in biochemical pharmacology from the university of southampton and a bs in biology and chemistry from the university of the west indies sign up for email alerts be the first to receive breaking news sign up today overview  amarantus bioscience holdings inc ambs amarantus bioscience holdings inc email alerts amarantus bioscience holdings inc on facebook amarantus bioscience holdings inc on linkedin amarantus bioscience holdings inc on twitter amarantus bioscience holdings inc on googleplus amarantus bioscience holdings inc rss home about navigation about amarantus bioscience holdings amarantus bioscience holdings inc is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology psychiatry ophthalmology and regenerative medicine and diagnostics in neurology the company’s lead therapeutic program eltoprazine is a small molecule indicated for the treatment of levodopainduced dyskinesia one of the most difficult problems facing patients with parkinson’s disease eltoprazine is currently in a phase b clinical trial with results from the study expected in  eltoprazine is also being evaluated for the treatment of adult attention deficit hyperactivity disorder adhd and alzheimer’s aggression amarantus recently completed the acquisition of cutanogen corporation cutanogen from lonza walkersville inc a subsidiary of lonza group ltd cutanogen has an exclusive worldwide license to intellectual property rights associated with engineered skin substitute ess ess is a full thickness skin replacement product prepared from autologous patients own tissueengineered skin cells in development for the treatment of severe burns ess received orphan drug designation from the fda for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting amarantus expects to commence a phase  study of ess in the us in the third quarter of  amarantus is also developing manf mesencephalicastrocytederived neurotrophic factor which was discovered by the company’s own discovery platform phenoguard manf is being developed for the treatment of brain and ophthalmic disorders and has received orphan drug designation from the fda and the european medicines agency ema for the treatment of retinitis pigmentosa the company’s diagnostics division amarantus diagnostics is dedicated to the development and commercialization of neurology diagnostic products the company’s lead diagnostic product lympro test® is a blood based assay to diagnose alzheimer’s disease and is approved for investigational use only to be used in biotech and pharmaceutical clinical trials amarantus diagnostics is also developing msprecise® a proprietary nextgeneration dna sequencing ngs assay for the identification of patients with relapsingremitting multiple sclerosis rrms at first clinical presentation the company is active exploring a number of strategic options for amarantus diagnostics including a potential spinoff to derive the full value of its premier neurodiagnostics business latest news april   •  am edt amarantus forms subsidiaries elto pharma to focus on cns disorders and manf therapeutics to focus on ophthalmology sign up for email alerts be the first to receive breaking news sign up today profile  amarantus bioscience holdings inc ambs amarantus bioscience holdings inc email alerts amarantus bioscience holdings inc on facebook amarantus bioscience holdings inc on linkedin amarantus bioscience holdings inc on twitter amarantus bioscience holdings inc on googleplus amarantus bioscience holdings inc rss investor presentation download our latest investor presentation download home investors company information profile navigation email alerts tear sheet contacts rss news feed profile business description amarantus bioscience holdings inc is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology psychiatry ophthalmology and regenerative medicine and diagnostics in neurology company info address montgomery streetsuite san francisco ca  us telephone  fax  emailinfoamarantuscom industry classifications sectorbiotechnology industrybiological products naicsbiological product manufacturing except diagnostic  sicbiological products except diagnostic  sign up for email alerts be the first to receive breaking news sign up today amarantus bioscience holdings inc ambs medical equipment deals and alliances profile report updated  prices from usd  — bioportfoliocom bioportfolio biotech healthcare and medical resources advertisement topics all topics biotechnology biotech business biotech products cancer cardiovascular dermatology drug discovery endocrinology gastroenterology immunology infectious diseases mental health neurology obstetrics orthopedics public health respiratory rheumatology urology  track topics on twitter track topics that are important to you printed from bioportfoliocom amarantus bioscience holdings inc ambs medical equipment deals and alliances profile report updated  prices from usd   edt  jul   bioportfolio reports summaryamarantus bioscience holdings inc amarantus formerly amarantus biosciences inc discovers and develops treatments for various therapeutic diseases the companys therapeutics pipeline products include eltoprazine and mesencephalicastrocytederived neurotrophic factor its diagnostics include lymphocyte proliferation test nuropro blood test and dna sequencing assay amarantus provides dna sequencing assay for the identification of patients with relapsingremitting multiple sclerosis at first clinical presentation the company also offers phenoguard protein discovery engine platform it provides products for cell cycle dysfunction endoplasmic reticulum stress astrocyteneuron biology neurodegeneration and apoptosis the company develops diagnostics and therapeutics pipeline products for diseases associated with neurodegeneration and apoptosis amarantus is headquartered in san francisco california the usamarantus bioscience holdings inc ambs medical equipment deals and alliances profile provides you comprehensive data and trend analysis of the companys mergers and acquisitions mas partnerships and financings the report provides detailed information on mergers and acquisitions equitydebt offerings private equity venture financing and partnership transactions recorded by the company over a five year period the report offers detailed comparative data on the number of deals and their value categorized into deal types subsector and regionsglobaldata derived the data presented in this report from proprietary inhouse medical etrack deals database and primary and secondary researchscope financial deals analysis of the companys financial deals including mergers and acquisitions equitydebt offerings private equity venture financing and partnerships deals by year chart and table displaying information encompassing the number of deals and value reported by the company by year for a five year period deals by type chart and table depicting information including the number of deals and value reported by the company by type such as mergers and acquisitions equitydebt offering etc deals by region chart and table presenting information on the number of deals and value reported by the company by region which includes north america europe asia pacific the middle east and africa and south and central america deals by subsector chart and table showing information on the number of deals and value reported by the company by subsector major deals information on the companys major financial deals each such deal has a brief summary deal type deal rationale and deal financials and target companys major public companies key financial metrics and ratios business description a brief description of the companys operations key employees a list of the key executives of the company important locations and subsidiaries a list and contact details of key centers of operation and subsidiaries of the company key competitors a list of the key competitors of the company key recent developments a brief on recent news about the companyreasons to buyget detailed information on the companys financial deals that enable you to understand the companys expansiondivestiture and fund requirements the profile enables you to analyze the companys financial deals by region by year by business segments and by type for a five year periodunderstand the companys business segments expansion  divestiture strategy the profile presents deals from the companys core business segments perspective to help you understand its corporate strategyaccess elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company detailed information on major recent deals includes a summary of each deal deal type deal rationale deal financials and target companys key financial metrics and ratiosequip yourself with detailed information about the companys operations to identify potential customers and suppliers the profile analyzes the companys business structure locations and subsidiaries key executives and key competitorsstay uptodate on the major developments affecting the company recent developments concerning the company presented in the profile help you track important eventsgain key insights into the company for academic or business research key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needsnote some sections may be missing if data is unavailable for the company related biotechnology pharmaceutical and healthcare news amarantus bioscience holdings inc ambs medical equipment deals and alliances profile updated  prices from usd  amarantus bioscience holdings inc ambs pharmaceuticals healthcare deals and alliances profile report updated  prices from usd  amarantus bioscience holdings inc ambs pharmaceuticals healthcare deals and alliances profile updated  prices from usd  amarantus bioscience holdings inc ambs pharmaceuticals healthcare deals and alliances profile updated  prices from usd  amarantus bioscience forms two new companies in restructuring operation original article amarantus bioscience holdings inc ambs medical equipment deals and alliances profile report updated  prices from usd  next article more from bioportfolio on amarantus bioscience holdings inc ambs medical equipment deals and alliances profile report updated  prices from usd  related companies related events related clinical trials related pubmed entries related medications quick linksadvanced search  login  subscribe  rss quick search advertisement   relevant topics bioscience bioscience  any of the sciences that deal with living organisms  the study of the nature behavior and uses of living organisms as applied to biology any of the branches of natural science dealing with living things such as their structure b bioinformatics bioinformatics is the application of computer software and hardware to the management of biological data to create useful information computers are used to gather store analyze and integrate biological and genetic information which can then be applied dna sequencing dna sequencing is the process of determining the precise order of nucleotides within a dna molecule during dna sequencing the bases of a small fragment of dna are sequentially identified from signals emitted as each fragment is resynthesized from a  news quicklinks search biotech medical and healthcare news popular biotech medical and healthcare news biotech news by article type biotech news by location bioportfolio bloggers publishing your news on bioportfolio recent visitor news searches bioportfolio limited about us contact us social media twitter  accounts twitter google linkedin publish content publish publish your press release advertise agreements agreements medical disclaimer privacy tools mybioportfolio rss help faqs sitemaps xml sitemap this site complies with the honcode standard for trustworthy health information verify here the information provided by bioportfoliocom is not a substitute for professional medical advice diagnosis or treatment the bioportfolio site is sponsored bioportfolio limited with offices at stafford house  prince of wales road dorchester dt pw england if you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “fair use” and legitimately infringes on your or your clients copyright we may be contacted concerning copyright matters at prioritybioportfoliocom all rights reserved all other trademarks recognized copyright   bioportfolio limited site developed by alacrify ltd amarantus bioscience holdings inc ambs  product pipeline analysis  update infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports amarantus bioscience holdings inc ambs  product pipe amarantus bioscience holdings inc ambs  product pipeline analysis  update wgr  may  global  pages globaldata description table of content sample report enquiry before buy related reports summaryamarantus bioscience has acquired rights to two diagnostic platforms for the diagnosis of neurodegenerative diseases and oncology such as nuropro diagnostic blood test platform and lympro alzheimers disease diagnostic blood test the company offers treatment services for neurodegenerative diseases such as parkinson’s disease als and alzheimer’s disease and cardiovascular diseases including myocardial infarction coronary artery disease and heart failure the company holds license to eltoprazine owns intellectual property rights for mesencephalicastrocytederived neurotrophic factor and license to the lympro test its partners include banyan biomarkers brewer sports international memory dx llc and psychogenics inc amarantus biosciences is headquartered in sunnyvale the usthis report is a source for data analysis and actionable intelligence on the company’s portfolio of pipeline products the report provides key information about the company its major products and brands the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantagescope the report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developments the report analyzes all pipeline products in development for the company amarantus bioscience holdings inc the report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial status the report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch date the report provides detailed description of products in development technical specification and functions the report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design  trial status and phase estimated start and end datereasons to buy develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape design and develop your product development marketing and sales strategies by understanding the competitor portfolio to formulate effective research  development strategies develop marketentry and market expansion strategies exploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust return plan mergers and acquisitions effectively by identifying key players of the most promising pipeline  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials stage and of development etc identify understand and capitalize the next highvalue products that your competitor would add in its portfolio table of contents table of contents list of tables list of figures amarantus bioscience holdings inc company snapshot amarantus bioscience holdings inc company overview key information amarantus bioscience holdings inc pipeline products and clinical trials overview amarantus bioscience holdings inc – pipeline analysis overview key facts amarantus bioscience holdings inc  major products and services amarantus bioscience holdings inc pipeline products by development stage amarantus bioscience holdings inc pipeline products overview lympro test lympro test product overview nuropro  als nuropro  als product overview nuropro  alzheimer’s disease nuropro  alzheimer’s disease product overview nuropro  breast cancer nuropro  breast cancer product overview nuropro  parkinsons disease nuropro  parkinsons disease product overview amarantus bioscience holdings inc  key competitors amarantus bioscience holdings inc  key employees amarantus bioscience holdings inc  locations and subsidiaries head office other locations  subsidiaries recent developments amarantus bioscience holdings inc recent developments apr   amarantus announces  year end financial results apr   amarantus appoints dr charlotte keywood chief medical officer of its therapeutics division apr   amarantus appoints robert farrell jd as chief financial officer mar   amarantus appoints dr louis kirby to board of advisors feb   amarantus strengthens management team with key additions in business development and regulatory affairs jan   amarantus establishes lympro research collaboration with boston university school of medicine nov   amarantus bioscience to present at the ld micro sixth annual conference on december   nov   amarantus appoints david a lowe phd to board of directors oct   amarantus to present at th annual livingston securities life science stakeholders summit oct   amarantus announces positive analytical performance data for lympro test for alzheimers disease appendix methodology about globaldata contact us disclaimer list of tables amarantus bioscience holdings inc key facts amarantus bioscience holdings inc pipeline products and clinical trials overview amarantus bioscience holdings inc pipeline products by equipment type amarantus bioscience holdings inc pipeline products by indication amarantus bioscience holdings inc key facts amarantus bioscience holdings inc major products and services amarantus bioscience holdings inc number of pipeline products by development stage amarantus bioscience holdings inc pipeline products summary by development stage lympro test  product status lympro test  product description nuropro  als  product status nuropro  als  product description nuropro  alzheimer’s disease  product status nuropro  alzheimer’s disease  product description nuropro  breast cancer  product status nuropro  breast cancer  product description nuropro  parkinsons disease  product status nuropro  parkinsons disease  product description amarantus bioscience holdings inc key employees amarantus bioscience holdings inc subsidiaries list of figures amarantus bioscience holdings inc pipeline products by equipment type amarantus bioscience holdings inc pipeline products by development stage  request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send amarantus bioscience holdings inc private company information  bloomberg july    am et biotechnology company overview of amarantus bioscience holdings inc snapshot people company overview amarantus bioscience holdings inc a biopharmaceutical company focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology psychiatry ophthalmology and regenerative medicine the company’s diagnostic products in development include the lymphocyte proliferation lympro test a diagnostic blood test for alzheimer’s disease and msprecise a proprietary dna sequencing assay for the identification of patients with multiple sclerosis its therapeutic products in development comprise eltoprazine a small molecule drug for the treatment of parkinson’s disease levadopainduced dyskinesia and attention deficit hyperactivity disorders and mesencephalic amarantus bioscience holdings inc a biopharmaceutical company focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology psychiatry ophthalmology and regenerative medicine the company’s diagnostic products in development include the lymphocyte proliferation lympro test a diagnostic blood test for alzheimer’s disease and msprecise a proprietary dna sequencing assay for the identification of patients with multiple sclerosis its therapeutic products in development comprise eltoprazine a small molecule drug for the treatment of parkinson’s disease levadopainduced dyskinesia and attention deficit hyperactivity disorders and mesencephalicastrocytederived neurotrophic factor for the treatment of various animal models including retinitis pigmentosa and retinal artery occlusion it also develops nuropro a neurodegenerative disease diagnostic platform with application in parkinson’s disease bcserapro an oncology diagnostic platform with application in breast cancer and phenoguard platform for neurrotrophic factor discovery in addition the company develops engineered skin substitute ess a cell therapybased autologous skin replacement product that is in midstage clinical development for the treatment of lifethreatening severe burns amarantus bioscience holdings inc has a cooperative research and development agreement with the us army institute of surgical research and rutgers university the company was formerly known as amarantus bioscience inc and changed its name to amarantus bioscience holdings inc in april  amarantus bioscience holdings inc was founded in  and is based in san francisco california detailed description  montgomery streetsuite san francisco ca united statesfounded in  employees phone  fax  wwwamarantuscom key executives for amarantus bioscience holdings inc mr gerald e commissiong chief executive officer president and director age  total annual compensation k mr marc e faerber vice president of financial operations treasurer secretary and corporate controller age  total annual compensation k dr john wesley commissiong phd chief scientific officer director and member of scientific advisory board age  total annual compensation k compensation as of fiscal year  amarantus bioscience holdings inc key developments amarantus bioscience holdings inc announces resignation of robert h trapp and ronald wei resigned as members of the board of directors may   on may   messrs robert h trapp and ronald wei resigned as members of the board of directors of amarantus bioscience holdings inc mr wei will continue to serve as the companys chief financial officer amarantus bioscience holdings inc establishes two new subsidiaries apr   amarantus bioscience holdings inc announced that it has formed a whollyowned subsidiary named elto pharma inc for the purpose of creating investment vehicles focused exclusively on the further development of eltoprazine amarantus midstage central nervous system cns symptomatic treatment for adult attention deficit and hyperactivity disorder adult adhd alzheimers aggression and parkinsons disease levodopainduced dyskinesia pdlid concurrently the company has formed the whollyowned subsidiary manf therapeutics inc for the purpose of the continued preclinical development of the internally discovered manf program in development for the treatment of ophthalmological disorders including the orphan indications retinitis pigmentosa rp and retinal artery occlusion rao in addition to glaucoma and parkinsons disease the companys phenoguard protein discovery engine that led to manfs discovery will also be an asset of manf therapeutics amarantus bioscience holdings inc names four new appointees to board of directors and interimcfo feb   sed biomedical inc and amarantus bioscience holdings inc have entered into a nonbinding letter of intent for amarantus to acquire as many as four of sed biomedicals biotechnology platforms four sed biomedical inc appointees to the amarantus board of directors rongguo ronald wei cpa cfo at sed development management llc as interimcfo of amarantus and board of directors steven spence managing director at dominick  dickerman as board of directors robert trapp gm at sed development llc management as board of directors and conn flanigan general counsel at global medical reit at board of directors similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target private placement april    private placement march    mergeracquisition february   biomedical assets request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact amarantus bioscience holdings inc please visit wwwamarantuscom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close market report amarantus bioscience holdings inc ambs  product pipeline analysis  update about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing amarantus bioscience holdings inc ambs  product pipeline analysis  update jul    globaldata   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents request details related amarantus bioscience holdings inc amarantus is a biotechnology company that discovers and develops treatments and diagnostics for diseases associated with neurodegeneration and apoptosis the company offers diagnostics and therapeutics pipeline products its diagnostics include lymphocyte proliferation test nuropro blood test and dna sequencing ngs assay amarantus provides dna sequencing ngs assay for the identification of patients with relapsingremitting multiple sclerosis rrms at first clinical presentation the companys therapeutics pipeline products include eltoprazine and mesencephalicastrocytederived neurotrophic factor manf it also offers phenoguard protein discovery engine platform the company provides products for cell cycle dysfunction endoplasmic reticulum stress astrocyteneuron biology neurodegeneration and apoptosis amarantus is headquartered in san francisco california the usthis report is a source for data analysis and actionable intelligence on the companys portfolio of pipeline products the report provides key information about the company its major products and brandsthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantagescopethe report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developmentsthe report analyzes all pipeline products in development for the company amarantus bioscience holdings incthe report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial statusthe report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch datethe report provides detailed description of products in development technical specification and functionsthe report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design  trial status and phase estimated start and end datereasons to buydevelop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscapedesign and develop your product development marketing and sales strategies by understanding the competitor portfolioto formulate effective research  development strategiesdevelop marketentry and market expansion strategiesexploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust returnplan mergers and acquisitions effectively by identifying key players of the most promising pipelineidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantagedevelop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials stage and of development etcidentify understand and capitalize the next highvalue products that your competitor would add in its portfolio table of contentstable of contentslist of tableslist of figuresamarantus bioscience holdings inc company snapshotamarantus bioscience holdings inc company overviewkey informationamarantus bioscience holdings inc pipeline products and clinical trials overviewamarantus bioscience holdings inc  pipeline analysis overviewkey factsamarantus bioscience holdings inc  major products and servicesamarantus bioscience holdings inc pipeline products by development stageamarantus bioscience holdings inc pipeline products overviewbiomarkerbased diagnostic assay  alzheimers diseasebiomarkerbased diagnostic assay  alzheimers disease product overviewdiagnostic assay  amyotrophic lateral sclerosisdiagnostic assay  amyotrophic lateral sclerosis product overviewdiagnostic assay  neuromyelitis opticadiagnostic assay  neuromyelitis optica product overviewdiagnostic assay  neurosarcoiddiagnostic assay  neurosarcoid product overviewdiagnostic assay  paraneoplastic diseasediagnostic assay  paraneoplastic disease product overviewdiagnostic test  alzheimers diseasediagnostic test  alzheimers disease product overviewdiagnostic test  bladder cancerdiagnostic test  bladder cancer product overviewdiagnostic test  ifnbeta resistancediagnostic test  ifnbeta resistance product overviewdiagnostic test  parkinsons diseasediagnostic test  parkinsons disease product overviewdiagnostic test  schizophreniadiagnostic test  schizophrenia product overviewdiagnostic test  thyroid cancerdiagnostic test  thyroid cancer product overviewlympro clia testlympro clia test product overviewlympro test  tbictelympro test  tbicte product overviewmsprecise  bloodmsprecise  blood product overviewmsprecise  csfmsprecise  csf product overviewnuropro  alsnuropro  als product overviewnuropro  alzheimers diseasenuropro  alzheimers disease product overviewnuropro  breast cancernuropro  breast cancer product overviewnuropro  parkinsons diseasenuropro  parkinsons disease product overviewamarantus bioscience holdings inc  key competitorsamarantus bioscience holdings inc  key employeesamarantus bioscience holdings inc  locations and subsidiarieshead officeother locations  subsidiariesrecent developmentsamarantus bioscience holdings inc recent developmentsjul   amarantus to commence trading on the otcqx marketplace under existing ticker symbol ambsjun   amarantus diagnostics announces acceptance of two latebreaking abstracts on lympro test data at the  alzheimers association international conferencemay   amarantus reports first quarter  financial results and business overviewmay   amarantus reports preliminary data from bloodbased version of msprecise diagnostic for multiple sclerosisapr   amarantus reports  financial results and business overviewmar   amarantus to present at the neurotech investing and partnering conference on tuesday april  feb   amarantus to present positive alzheimers disease biomarker data on the lympro test at the th international conference on alzheimers and parkinsons diseases and related neurological disordersfeb   amarantus announces first alzheimers biomarker services collaboration for lympro test with anavex life sciencesjan   amarantus forms alzheimers disease diagnostics scientific advisory boardjan   amarantus announces positive data from  subject lp clinical study of lympro test confirming statistically significant markers for alzheimersappendixmethodologyabout globaldatacontact usdisclaimerlist of tablesamarantus bioscience holdings inc key factsamarantus bioscience holdings inc pipeline products and clinical trials overviewamarantus bioscience holdings inc pipeline products by equipment typeamarantus bioscience holdings inc pipeline products by indicationamarantus bioscience holdings inc key factsamarantus bioscience holdings inc major products and servicesamarantus bioscience holdings inc number of pipeline products by development stageamarantus bioscience holdings inc pipeline products summary by development stagebiomarkerbased diagnostic assay  alzheimers disease  product statusbiomarkerbased diagnostic assay  alzheimers disease  product descriptiondiagnostic assay  amyotrophic lateral sclerosis  product statusdiagnostic assay  amyotrophic lateral sclerosis  product descriptiondiagnostic assay  neuromyelitis optica  product statusdiagnostic assay  neuromyelitis optica  product descriptiondiagnostic assay  neurosarcoid  product statusdiagnostic assay  neurosarcoid  product descriptiondiagnostic assay  paraneoplastic disease  product statusdiagnostic assay  paraneoplastic disease  product descriptiondiagnostic test  alzheimers disease  product statusdiagnostic test  alzheimers disease  product descriptiondiagnostic test  bladder cancer  product statusdiagnostic test  bladder cancer  product descriptiondiagnostic test  ifnbeta resistance  product statusdiagnostic test  ifnbeta resistance  product descriptiondiagnostic test  parkinsons disease  product statusdiagnostic test  parkinsons disease  product descriptiondiagnostic test  schizophrenia  product statusdiagnostic test  schizophrenia  product descriptiondiagnostic test  thyroid cancer  product statusdiagnostic test  thyroid cancer  product descriptionlympro clia test  product statuslympro clia test  product descriptionlympro test  tbicte  product statuslympro test  tbicte  product descriptionmsprecise  blood  product statusmsprecise  blood  product descriptionmsprecise  csf  product statusmsprecise  csf  product descriptionnuropro  als  product statusnuropro  als  product descriptionnuropro  alzheimers disease  product statusnuropro  alzheimers disease  product descriptionnuropro  breast cancer  product statusnuropro  breast cancer  product descriptionnuropro  parkinsons disease  product statusnuropro  parkinsons disease  product descriptionamarantus bioscience holdings inc key employeesamarantus bioscience holdings inc subsidiarieslist of figuresamarantus bioscience holdings inc pipeline products by equipment typeamarantus bioscience holdings inc pipeline products by development stage this report does not have a list of companies mentioned available this report does not have a press release associated with it order today format single user pdf  delivered by email  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher globaldata is a leading provider of global business intelligence including market competitor product and customer information it provides indepth research analysis data and forecasts through a range of interactive online databases reports and management briefings globaldata has a large team of experienced research and analysis consulting and marketing experts it has a global presence including key offices in the us europe and asia the group has over  years of experience of delivering market intelligence data and analysis and a highly experienced senior management team publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc ambs key statistics  amarantus bioscience holdings inc financial ratios  marketwatch bulletin investor alert tokyo markets close in currencies europe markets london markets expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close amarantus bioscience holdings inc otc ambs go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus amarantus bioscience holdings inc market closed  quotes are delayed by  min jul    pm ambs quoteszigmandelayed   change   volume volume  quotes are delayed by  min quoteszigmandelayed previous close     change   day low day high    week low  week high   company description amarantus bioscience holdings inc is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology psychiatry ophthalmology and regenerative medicine and diagnostics in neurology the company was found amarantus bioscience holdings inc is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology psychiatry ophthalmology and regenerative medicine and diagnostics in neurology the company was founded by gerald e commissiong and john w commissiong on january   and is headquartered in san francisco ca valuation pe current  pe ratio with extraordinary items  enterprise value to ebitda  total debt to enterprise value  efficiency income per employee  liquidity current ratio  quick ratio  cash ratio  profitability return on assets  capital structure total debt to total assets  officers and executives name age officer since title mr gerald e commissiong   president chief executive officer  director dr elise brownell   senior vpoperations  program management mr rongguo wei   chief financial officer dr john w commissiong   director  chief scientific officer mr steven d spence   director insider actions – purchase – sale  – number of transactions  newslatestcompanyusambs marketwatch news on ambs no news currently available for ambs newsnonmarketwatchcompanyusambs other news on ambs amarantus to be awarded european patent covering manf  pm feb    seeking alpha amarantus bios eltoprazine an orphan drug for levodopainduced movement disorder  am feb    seeking alpha premarket biotech digest exelixis rallies shirebaxalta deal lipocine commences midstage study  am jan    seeking alpha premarket biotech digest dynavax pullback tevatakeda venture valeant ceo hospitalized  am dec    seeking alpha premarket biotech digest celldexs catalyst shirebaxalta deal psivida surges  am dec    seeking alpha premarket biotech digest achaogens potential kalobios fires shkreli halozymelilly deal  am dec    seeking alpha premarket biotech digest portolas milestone shkreli resigns biomarin dmd drug  am dec    seeking alpha premarket biotech digest shkreli arrested exelixis catalyst gileadgalapagos deal  am dec    seeking alpha premarket biotech digest acadia set for gains intercept takeover rumors clovis update  am dec    seeking alpha premarket biotech digest biogen looks stronger atara plunges akebia collaboration  am dec    seeking alpha premarket biotech digest gileads upside shirebaxalta deal ariad lowers guidance  am dec    seeking alpha premarket biotech digest portola insider buying pfizer advances avelumab caras positive data  am dec    seeking alpha premarket biotech digest relypsa undervalued northwest forms committee oncothyreon tumbles  am dec    seeking alpha premarket biotech digest arrowheads arc data bluebird tumbles gilead looking for acquisitions  am dec    seeking alpha premarket biotech digest gilead and hcv drug pricing relypsa rumors amgenmerck collaboration  am dec    seeking alpha premarket biotech digest progenics milestone cellectis conference call alexions strensiq  am dec    seeking alpha premarket biotech digest hcv drug pricing astrazenecas presentation zafgen tumbles  am dec    seeking alpha premarket biotech digest fibrogens gains anavex data geron rallies  am dec    seeking alpha premarket biotech digest cti biopharma undervalued shires new bid biomarins dmd drug review  am nov    seeking alpha premarket biotech digest celldexs upside roches encouraging data canfite surges  am nov    seeking alpha loading more headlines at a glance amarantus bioscience holdings inc  montgomery street suite  san francisco california  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue na net income m employees  annual report for ambs newspressreleasecompanyusambs press releases on ambs avant diagnostics highlights published clinical utility data for theralink® mtor pathway activation data predicting tamoxifen® and other endocrine treatment response in estrogen receptor positive er breast cancer  am july    pr newswire  prf avant diagnostics acquires exclusive option to license genetic health solution technology platform  pm july    pr newswire  prf amarantus forms subsidiaries elto pharma to focus on cns disorders and manf therapeutics to focus on ophthalmology  am april    pr newswire  prf amarantus provides update on restructuring efforts and letter of intent with sed biomedical inc  pm april    pr newswire  prf amarantus enters into a letter of intent to acquire certain biotechnology assets from sed biomedical inc  pm feb    pr newswire  prf amarantus announces passing of biotechnology legend dr joseph rubinfeld  am feb    pr newswire  prf amarantus announces publication of human clinical data for engineered skin substitute in the treatment of lifethreatening pediatric severe burns  am aug    pr newswire  prf trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest awynn macau net profit rises  on year ahere’s why oil just scored its biggest oneday rally of  aoil rally continues as optimism builds ahead us supply data ajapan aussie stocks continue to rise spurred on by commodity prices adon’t have a college degree these are the industries with the bestpaid jobs pdoes your child have a question there’s a smart toy for that phouse votes to prevent disgruntled customers from being able to sue their bank pwhat everyone can learn from jared kushner’s unorthodox approach to meetings pone depressing reason millions of people are locked out of the american dream pone version of gop healthcare bills fails in senate vote pgeorge clooney and angelina jolie’s directorial projects could be the most soughtafter tickets at tiff pjohn mccain gives trump a win then gives senate an earful ppaypal earnings partnerships help but are benefits already priced in pamd puts intel in the crosshairs with fastandcheap threadripper chip pamd earnings give investors what they wanted now it must deliver phouse passes bill hitting russia with new sanctions pwsj interview trump doesnt rule out firing sessions pformer trump campaign chief manafort strikes deal to avoid public testimony pthis quant pro and card counter says gambling can make you a better investor pbitcoin digital currencies retreat from records loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  amarantus bioscience holdings inc ambs amarantus bioscience holdings inc email alerts amarantus bioscience holdings inc on facebook amarantus bioscience holdings inc on linkedin amarantus bioscience holdings inc on twitter amarantus bioscience holdings inc on googleplus amarantus bioscience holdings inc rss pioneering research developing therapeutic and diagnostic products for neurological disorders and orphan indications learn more pioneering research developing therapeutic and diagnostic products for neurological disorders and orphan indications learn more pioneering research developing therapeutic and diagnostic products for neurological disorders and orphan indications learn more therapeutics pipeline amarantus specializes in the identification and acquisition of undervalued assets that have the potential to address huge unmet medical needs we are dedicated to building and developing a robust pipeline of therapeutic candidates in neurology and ophthalmology diseases and regenerative medicine view pipeline phase preclinical phase  phase  phase  market eltoprazine parkinsons pdlid preclinical phase completed phase  phase completed phase  phase in progress phase  phase not started market phase not started eltoprazine adult adhd preclinical phase completed phase  phase completed phase  phase in progress phase  phase not started market phase not started eltoprazine alzheimers aggression preclinical phase completed phase  phase in progress phase  phase not started phase  phase not started market phase not started ess intractable severe burns preclinical phase completed phase  phase completed phase  phase in progress phase  phase not started market phase not started manf retinitis pigmentosa preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started market phase not started manf parkinsons disease preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started market phase not started source develop and monetize highly undervalued biopharma assets three pillars of expected transformational growth amarantus has a focus on developing certain small molecules biologics and biomarkers surrounding intellectual property and proprietary technologies it owns therapeutics eltoprazine manf engineered skin substitute ess discovery phenoguard latest news april   •  am edt amarantus forms subsidiaries elto pharma to focus on cns disorders and manf therapeutics to focus on ophthalmology april   •  pm edt amarantus provides update on restructuring efforts and letter of intent with sed biomedical inc february   •  pm est amarantus enters into a letter of intent to acquire certain biotechnology assets from sed biomedical inc social media ambs results indicate that autologous esss reduce mortality  requirements for donor skin harvesting httpstcomdrkdfi august    pm investor presentation view our latest corporate presentation view presentation stock info view investor relations › otcpink ambs change volume market cap sign up for email alerts be the first to receive breaking news sign up today bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one